Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results